Indicated as adjunct to diet and exercise to improve glycemic control with type 2 diabetes mellitus (DM).
Exenatide acetate powder,Exenatide powder2 mg SC qWeek
Initiating therapy
Prior treatment with immediate- or extended-release exenatide product is
not required when initiating Bydureon or Bydureon BCise therapy
If starting Bydureon or Bydureon BCise in a patient already taking Byetta, discontinue Byetta
Patients may experience transient (~2-4 weeks) elevations in blood glucose concentrations
Dosage Modifications
Hepatic impairment: Not studied
Renal impairment
Pharmacokinetic studies indicated an increase in exposure in moderate
and mild renally impaired patients as compared to patients with normal
renal function
Mild (eGFR >45 mL/min/1.73 m²): Monitor for adverse reactions that may lead to hypovolemia
Severe (eGFR
